论文部分内容阅读
目的:探讨细胞角蛋白20(CK20)在乳腺癌组织中的表达及其与乳腺癌进展、转移和预后的相关性。方法:选取乳腺癌患者86例,以20例乳腺良性肿瘤组织作为对照,应用免疫组织化学染色方法检测CK20的表达,并分析其与乳腺癌临床病理特征及预后的关系。结果:CK20在乳腺癌组织中的阳性表达率为80.23%(69/86),明显高于在乳腺良性肿瘤中的表达[20.00%(4/20),P<0.01]。CK20的表达与乳腺癌组织学分级(P<0.05)和病理类型(P<0.01)有关,与TNM分期(r=0.86,P<0.05)、淋巴结转移(r=0.73,P<0.05)和HER-2(r=0.69,P<0.05)呈正相关,与ER(r=-0.58,P<0.05)呈负相关。CK20阳性表达组和CK20阴性表达组的5年生存率分别为38.46%(25/65)和66.67%(10/15),差异有统计学意义(P<0.01)。结论:CK20与乳腺癌的进展、转移有关,作为新的乳腺癌标记物,有一定的临床实际应用价值。
Objective: To investigate the expression of cytokeratin 20 (CK20) in breast cancer and its relationship with the progression, metastasis and prognosis of breast cancer. Methods: Totally 86 patients with breast cancer were selected. Twenty cases of benign breast tumor tissues were used as control. The expression of CK20 was detected by immunohistochemical staining and the relationship between the expression of CK20 and the clinicopathological features and prognosis of breast cancer was analyzed. Results: The positive expression rate of CK20 in breast cancer tissues was 80.23% (69/86), which was significantly higher than that in benign breast tumors [20.00% (4/20), P <0.01]. The expression of CK20 was correlated with histological grade (P <0.05) and pathological type (P <0.01) in breast cancer, but not with TNM stage (r = 0.86, P <0.05), lymph node metastasis -2 (r = 0.69, P <0.05), but negatively correlated with ER (r = -0.58, P <0.05). The 5-year survival rates of CK20-positive group and CK20-negative group were 38.46% (25/65) and 66.67% (10/15), respectively, with statistical significance (P <0.01). Conclusion: CK20 is associated with the progression and metastasis of breast cancer. As a new marker of breast cancer, CK20 has some clinical practical value.